About ALDX

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjögren-Larsson Syndrome, noninfectious anterior uveitis, and allergic conjunctivitis. NS2 has not been approved for sale in the U.S. or elsewhere.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ALDX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 105.8 M 1.05784E+08 2,016 2016 0.0% 2.21903E-05 7 K 7372
UWM ProShares Ultra Russell2000 184.1 M 1.84148E+08 2,016 2016 0.0% 2.96635E-05 12 K 12000
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.7 B 1.87292E+10 3,568 3568 0.0% 0 42 K 41634
IWC iShares Microcap ETF 916.2 M 9.16246E+08 1,452 1452 0.05% 0.0005 414 K 413835
IWM iShares Russell 2000 ETF 44.9 B 4.48577E+10 2,006 2006 0.01% 0.0001 3.7 M 3702290
IWO iShares Russell 2000 Growth ETF 9.3 B 9.28872E+09 1,239 1239 0.02% 0.0002 1.5 M 1474960
IWV iShares Russell 3000 ETF 9.7 B 9.71954E+09 2,931 2931 0.0% 0 101 K 101096

Wait, Before You Leave...